Figure EV4. Application of the assay to breast cancer PDX tissue samples.

• A
  Levels of AKT pS473, AKT pT308, AKT1S1 pT246, and AKT2 pS474 which are all pharmacodynamic markers for PI3K inhibition observed using SigPath. For each graph, and treatment in each graph, the WHIM/PDX models are sorted in the order of their resistance to the drug with least resistance on the left. Across all markers, the most resistant model (WHIM12) is the least affected at 50 h of buparlisib treatment. P‐values, in round brackets “()”, are calculated from a one‐sample t‐test, compared to a hypothetical mean of 0, using all WHIMS as replicates for a certain treatment.
• B
  Bar and whisker plot showing the range of ratios obtained for the overlapped 115 peptides in discovery study using TMT and SigPath. For the discovery study, Log₂ ratio of all the peptides to the pooled reference was used for the plot. For SigPath, Log₂ ratio of light to heavy peptide was used for the plot.